San Diego, CA — Oct. 13, 2005 — Kalypsys, a privately-owned drug discovery company, announced today the expansion of its Kalypsys Systems product offering to meet customer interest in drug discovery tools. Known for its fully automated, high-throughput screening (HTS) systems with 1536 well format, capable of screening more than 1 million compounds per day, the company is introducing new, smaller configurations of the Kalypsys Integrated Screening System tailored to meet the needs of a wider range of HTS users. Specifically, the new compound profiling capabilities and an automated protein production and purification system are designed to provide improved productivity and increased flexibility for drug discovery efforts.
"We are seeing significant interest in HTS driven by academic institutions and biotechnology companies seeking the performance capabilities usually reserved for large pharmaceutical companies," commented Rodney Turner, Executive Director, World Wide Systems Sales. "These latest additions to our product offerings reflect Kalypsys' continuing commitment to innovation in drug discovery technology."
Kalypsys developed the smaller version of its Integrated HTS System with various configurations to address the needs of users who seek broad assay capability across a wide range of cellular and biochemical assays coupled with on-board compound storage capability for several hundred thousand compounds. This entry level HTS system is particularly relevant to first-time customers and will appeal to established screening operations seeking greater flexibility and capability in a variety of assay formats.
"Our focus on quality and customer service combined with broad scientific expertise is an important strategic advantage for our systems business," commented Court R. Turner, Vice President, Strategic Alliances of Kalypsys. "As Kalypsys' internal drug discovery efforts reach new milestones with lead programs planned to enter the clinic in late 2005 and early 2006, it is exciting that the Kalypsys systems business is also making great strides in its development."
One new configuration of the Kalypsys System provides unmatched capabilities for the profiling of large and small compound libraries. This focused functionality addresses a key bottleneck in the drug discovery process or it can be used for chemical genomics applications. Detailed chemical mapping of compound libraries ranging from thousands to several million in cell-based or biochemical assays is seamless and fully integrated in the 1536 well format.
In addition, the new automated Kalypsys Protein Production and Purification System is a response to increased customer interest in biological therapeutics, especially when working in tandem with a Kalypsys integrated Screening System. This "turnkey" solution enables the production and purification of 96 different proteins from bacterial culture in a single day with minimal human intervention. All of these new products are available immediately from Kalypsys.
To date, Kalypsys has announced technology transfer partnerships of their Kalypsys Screening Systems with Merck & Co., Inc, the National Institutes of Health, Los Alamos National Laboratories and most recently The Scripps Research Institute Florida.
Kalypsys is a privately owned San Diego small molecule drug discovery and development company that is applying its integrated drug discovery infrastructure, suite of ultra-high throughput lead discovery technologies, and seasoned team of scientists to advance its pipeline into clinical development. Kalypsys uses its technologies, integrated capabilities and sizeable drug-like compound collection to improve the drug discovery research process and generate a robust pipeline for itself and its partners. Kalypsys' mission is to participate in targeted commercial opportunities by building a sustainable drug candidate pipeline from target to proof of efficacy and safety in the clinic with unmatched speed, efficiency, and success rates. For more information on Kalypsys, please visit www.kalypsys.org.